Visunex Raises $20 Million in Series B Funding for Newborn Imaging Technology

May 12, 2017: By Jon Swedien

Vixunex logoVisunex Medical Systems, a manufacturer of advanced wireless, wide-field imaging systems for newborn infants, raised $20 million in a Series B funding, the Fremont, California, company announced May 5.

The firm introduced in 2016 the first wireless digital imaging platform for imaging the eye of neonatal and full term infants—the PanoCam LT.

“This new round of funding brings the total investment into Visunex Medical to $32 million and will allow the company to expand manufacturing operations to meet the market demand,” said Wei Su, PhD, Visunex’ founder and CEO.

Su said Visunex will also use the money to increase research and development.

Visunex said It will soon be adding a third imaging system to the PanoCam family, which currently consists of the LT and Pro wireless wide-field imaging systems. The new configuration is intended to expand the newborn and infant imaging market, the company said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022